KaloBios distancing itself from Martin Shkreli with new drug pricing model
In the wake of its relationship with Martin Shkreli, KaloBios' new CEO Cameron Durrant "wants to clean up the messy legacy and start afresh," he said.
Monoclonal antibody player KaloBios shutting down
The long-beleaguered monoclonal antibody developer KaloBios is finally winding down operations - after a constant stream of setbacks since its February 2013 IPO.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.